医学
回顾性队列研究
血管成形术
狭窄
动静脉瘘
外科
比例危险模型
气球
放射科
瘘管
内科学
队列
新生内膜增生
逻辑回归
血管疾病
内膜增生
队列研究
单变量分析
心脏病学
阶段(地层学)
病变
作者
Chaojiang Su,Chengwen Dang,Huan Wu,Yan Jiang,Yiping Yan,王丽珠,Guanglei Chen,Liting Liu,Yan Chen,Zongyang Liu,Bin Zhao,Yunzhi Chen
标识
DOI:10.3389/fcell.2026.1977789
摘要
Background Recurrent autogenous arteriovenous fistula (AVF) stenosis occurs in a vascular environment in which injury, neointimal hyperplasia and inflammation may coexist. Whether routine inflammatory or hematological markers contribute to clinical prognosis after drug-coated balloon (DCB) angioplasty remains uncertain. This retrospective study examines clinical outcomes and inflammation-related prognostic associations without assuming that inflammatory pathways were measured or causally established. Methods This single-center retrospective cohort comprised 357 patients treated between February 2023 and May 2026. The primary outcome was time from index DCB angioplasty to clinically driven target-lesion reintervention. Kaplan–Meier and Cox analyses used available follow-up; a separate clinical logistic model addressed failure within 12 months in 356 patients with complete model data. No non-DCB comparator or patient-level molecular measurements were available. Results Mean brachial-artery flow increased from 288.98 ± 139.37 to 980.92 ± 174.66 mL/min and minimal luminal diameter from 1.52 ± 0.50 to 5.21 ± 0.63 mm (both P < 0.001). Kaplan–Meier primary patency was 95.24%, 84.03%, 68.90%, and 55.40% at 3, 6, 9, and 12 months. In the extended Cox model (338 patients; 191 events), previous PTA count (HR 1.129 per procedure, P = 0.003) and lesion length (HR 1.105 per cm, P = 0.001) were associated with greater hazard; postprocedural flow (HR 0.889 per 100 mL/min, P = 0.014) and red-blood-cell count (HR 0.804 per 10 12 /L, P = 0.027) were associated with lower hazard. The five-fold cross-validated AUC of the clinical 12-month model was 0.706. Conclusion In this selected single-center cohort, recurrent AVF stenosis after DCB angioplasty was associated with previous PTA burden, lesion length, postprocedural flow, and red-blood-cell count. Routine blood-cell measures provide an exploratory inflammation-related clinical context but do not establish inflammatory mechanisms or validate a specific inflammatory biomarker. Independent validation and patient-level inflammatory measurements are required.
科研通智能强力驱动
Strongly Powered by AbleSci AI